639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial
Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt
{"title":"639 Management of immune-related adverse events in patients with primary advanced or recurrent endometrial cancer: dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG-3031/RUBY trial","authors":"Z. Novák, Michael A Gold, Jørn Herrstedt, S. Gill, Antonella Savarese, John Diaz, Stefan Kommoss, Guilherme Cantuaria, I. Boere, E. Fleming, L. Gilbert, K. Pennington, R. Holloway, E. Miller, Rachel Miller, M. Powell, Christine Dabrowski, S. Stevens, M. Mirza, C. Mccourt","doi":"10.1136/ijgc-2024-esgo.34","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":517822,"journal":{"name":"Oral Sessions","volume":"27 6","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oral Sessions","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1136/ijgc-2024-esgo.34","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
